JP4994038B2 - 一倍体接合方法を用いた酵母におけるヘテロ多量体のポリペプチド類の合成方法 - Google Patents
一倍体接合方法を用いた酵母におけるヘテロ多量体のポリペプチド類の合成方法 Download PDFInfo
- Publication number
- JP4994038B2 JP4994038B2 JP2006536888A JP2006536888A JP4994038B2 JP 4994038 B2 JP4994038 B2 JP 4994038B2 JP 2006536888 A JP2006536888 A JP 2006536888A JP 2006536888 A JP2006536888 A JP 2006536888A JP 4994038 B2 JP4994038 B2 JP 4994038B2
- Authority
- JP
- Japan
- Prior art keywords
- pichia pastoris
- diploid
- yeast cells
- expression
- doublings
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims description 80
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 49
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 48
- 229920001184 polypeptide Polymers 0.000 title claims description 47
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims description 43
- 230000021615 conjugation Effects 0.000 title claims description 14
- 230000015572 biosynthetic process Effects 0.000 title description 14
- 238000003786 synthesis reaction Methods 0.000 title description 11
- 241000235058 Komagataella pastoris Species 0.000 claims description 78
- 210000004027 cell Anatomy 0.000 claims description 52
- 230000014509 gene expression Effects 0.000 claims description 52
- 210000005253 yeast cell Anatomy 0.000 claims description 42
- 108060003951 Immunoglobulin Proteins 0.000 claims description 32
- 102000018358 immunoglobulin Human genes 0.000 claims description 32
- 210000003783 haploid cell Anatomy 0.000 claims description 21
- 241000235648 Pichia Species 0.000 claims description 20
- 239000001963 growth medium Substances 0.000 claims description 17
- 230000028327 secretion Effects 0.000 claims description 17
- 239000002609 medium Substances 0.000 claims description 13
- 230000004927 fusion Effects 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 230000002194 synthesizing effect Effects 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 4
- 229940072221 immunoglobulins Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 123
- 102000004169 proteins and genes Human genes 0.000 description 65
- 235000018102 proteins Nutrition 0.000 description 59
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 35
- 239000013604 expression vector Substances 0.000 description 32
- 239000013598 vector Substances 0.000 description 24
- 238000004519 manufacturing process Methods 0.000 description 23
- 210000001840 diploid cell Anatomy 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 230000012010 growth Effects 0.000 description 15
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 14
- 101150050575 URA3 gene Proteins 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 108010076504 Protein Sorting Signals Proteins 0.000 description 13
- 238000013518 transcription Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 208000035199 Tetraploidy Diseases 0.000 description 9
- 108010084455 Zeocin Proteins 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 9
- 230000009466 transformation Effects 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- 230000013011 mating Effects 0.000 description 8
- 230000006798 recombination Effects 0.000 description 8
- 238000005215 recombination Methods 0.000 description 8
- 230000003248 secreting effect Effects 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 101100455752 Caenorhabditis elegans lys-3 gene Proteins 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 241000235070 Saccharomyces Species 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 101000931108 Mus musculus DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- LXJXRIRHZLFYRP-UHFFFAOYSA-N glyceraldehyde 3-phosphate Chemical compound O=CC(O)COP(O)(O)=O LXJXRIRHZLFYRP-UHFFFAOYSA-N 0.000 description 5
- 239000006151 minimal media Substances 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000001851 biosynthetic effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 230000016784 immunoglobulin production Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- SEHFUALWMUWDKS-UHFFFAOYSA-N 5-fluoroorotic acid Chemical compound OC(=O)C=1NC(=O)NC(=O)C=1F SEHFUALWMUWDKS-UHFFFAOYSA-N 0.000 description 3
- -1 FACE Proteins 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 210000000628 antibody-producing cell Anatomy 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000021121 meiosis Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 101100502336 Komagataella pastoris FLD1 gene Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 241000320412 Ogataea angusta Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101800001442 Peptide pr Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 101100421128 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SEI1 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- SBKVPJHMSUXZTA-MEJXFZFPSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 SBKVPJHMSUXZTA-MEJXFZFPSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000178289 Botryozyma Species 0.000 description 1
- 241000722885 Brettanomyces Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000589877 Campylobacter coli Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108050001186 Chaperonin Cpn60 Proteins 0.000 description 1
- 102000052603 Chaperonins Human genes 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 241001508787 Citeromyces Species 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000235035 Debaryomyces Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 241001465321 Eremothecium Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 102100022087 Granzyme M Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
- 101000900697 Homo sapiens Granzyme M Proteins 0.000 description 1
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102100029571 Immunoglobulin J chain Human genes 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 101710122479 Isocitrate lyase 1 Proteins 0.000 description 1
- 241000235644 Issatchenkia Species 0.000 description 1
- 241001233945 Kazachstania Species 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241001302784 Kodamaea Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241001508815 Lodderomyces Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010038049 Mating Factor Proteins 0.000 description 1
- UASDAHIAHBRZQV-YUMQZZPRSA-N Met-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N UASDAHIAHBRZQV-YUMQZZPRSA-N 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241001452677 Ogataea methanolica Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000235652 Pachysolen Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000982698 Prorodonopsis coli Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101100289886 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) LYS4 gene Proteins 0.000 description 1
- 241000235344 Saccharomycetaceae Species 0.000 description 1
- 241001149673 Saturnispora Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 241000183049 Tetrapisispora Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000235006 Torulaspora Species 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 241000235152 Williopsis Species 0.000 description 1
- 241000235017 Zygosaccharomyces Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000001651 autotrophic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 101150038738 ble gene Proteins 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 108010014507 erythroagglutinating phytohemagglutinin Proteins 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000007850 fluorescent dye Chemical group 0.000 description 1
- 108091005749 foldases Proteins 0.000 description 1
- 102000035175 foldases Human genes 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000007973 glycine-HCl buffer Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 101150051897 his5 gene Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000046768 human CCL2 Human genes 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 101150054280 lys-3 gene Proteins 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 108010027345 wheylin-1 peptide Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Description
組み換えたんぱく質生産は、高速大量処理スクリーニング、機能性の検証、構造生物学および医薬ポリペプチド類の生産にとっては必須な活動である。Escherichia coli(大腸菌)は、低価格の基質において高細胞密度まで容易に増殖し、確立した遺伝手法および発現ベクター類を有するので、異種性たんぱく質の発現に広く使用される生物である。しかしながら、大腸菌は活性な生物分子を効率的に生産するには必ずしも十分ではない。生物的活性であるためには、ポリペプチド鎖はジスルフィド結合群の適切な形成を含めて正確に生来の三次元構造に折り畳まれていなければならず、複数の鎖の正確な会合を更に必要とする。
形質転換受容性酵母を接合することで組み換えヘテロ多量体たんぱく質群の合成と分泌するための方法が提供される。関心のあるヘテロ多量体たんぱく質群は少なくとも2種の非同一ポリペプチド鎖群、例えば抗体の重鎖および軽鎖群、MHCのアルファおよびベータ鎖群などを含む。発現ベクターは各非同一ポリペプチド鎖用に提供される。
組み換えヘテロ多量体たんぱく質は接合形質転換受容性酵母の二倍体菌株から分泌される。遺伝的に標識した酵母一倍体細胞の対はヘテロ多量体たんぱく質のサブユニットを含む発現ベクター群により形質転換される。1個の一倍体細胞は最初の発現ベクターを含み、別の一倍体細胞は別の発現ベクターを含む。場合によりヘテロ三量体、ヘテロ四量体などの合成のために、更なる発現ベクターを一倍体または二倍体細胞に導入してもよいし;或いは当該最初または別の発現ベクターは更なるコード配列群を含むことができる。非同一ポリペプチドの発現レベルは適当な選択、ベクター複製物数、プロモーターの強さおよび/または誘導などにより個々に較正され、調整される。当該形質転換した一倍体細胞群は遺伝的に交雑させるか融合させる。得られた二倍体または四倍体菌株は完全に組み立てられそして生物的機能性ヘテロ多量体たんぱく質を産生し、分泌するために利用される。
本発明は特定の方法論、手順、細胞菌株、動物種または属および記載した試薬に限られることはなく、変化してもよいと理解すべきものである。また本明細書で使用される専門用語は説明する特定の実施形態のみを説明する目的のためで、本発明の目的を制限する意図は無く、本発明は添付した請求項のみに制限されるであろう。
形質転換した接合形質転換受容性一倍体酵母細胞群は、望ましいたんぱく質のサブユニット対形成を可能とする遺伝的方法を提供する。一倍体酵母菌株群は2つの発現ベクターのそれぞれにて形質転換され、最初のベクターは1つのポリペプチド鎖の合成を導き、別のベクターは別の非同一ポリペプチド鎖の合成を導く。当該2つの一倍体菌株を接合させて、最適化標的たんぱく質産生が得られる二倍体宿主を供する。
抗体遺伝子群:キメラヒト化マウスモノクローナル抗体OKT3の3種類の形態の合成を目指し、遺伝子群をクローン化し、組み立てた。これらの当該組立物において使用する可変領域の出所はGenbankで見出すことができる。受入番号A22261;マウスOKT3重鎖(International Patent Application WO 9109967‐A 3 11‐JUL‐1991)。受入番号A22259;マウスOKT3軽鎖(International Patent Application WO 9109967‐A 3 11‐JUL‐1991)。
軽鎖および重鎖抗体遺伝子群の転写用pGAPZ‐アルファ発現ベクター群の作成。軽鎖および重鎖の両方の可変領域をクローン化するために、マウスOKT3 CD3ハイブリドーマの細胞菌株の細胞群を増殖させ、全RNAを抽出した。その後2種のRT‐PCR反応を実施したが、1種はOKT3抗体遺伝子群の軽鎖に特異的であり、1種はOKT3抗体遺伝子群の重鎖可変領域コード化配列群に特異的であった。当該重鎖および軽鎖可変領域を増幅するために使用したプライマー群はそれぞれの可変領域群に関して(SEQ ID NO:1)5'‐CCGCTCGAGAAAAGAGAGGCTGAAGCTCAGGTCCAGCTGCAGCAGTC‐3'および(SEQ ID NO:3)5'‐CCGCTCGAGAAAAGAGAGGCTGAAGCTCAAATTGTTCTCACCCAGTCTCC‐3'とともに(SEQ ID NO:2)5'‐TGGGCCCTTGGTGGAGGCTGAGGAGACTGTGAGAGTGGTGC‐3'および(SEQ ID NO:4)5'‐GACAGATGGTGCAGCCACAGCCCGG TTTATTTCCAACTTTGTCC‐3'であった。
Claims (30)
- 分泌される生物学的に活性のある完全な免疫グロブリンを合成及び回収する方法であって;
(i)1倍体ピキア パストリス(Pichia pastoris)酵母細胞の接合またはスフェロプラスト融合により、安定した2倍体ピキア パストリス(Pichia pastoris)酵母細胞を作製し、ここで該2倍体ピキア パストリス(Pichia pastoris)酵母細胞は接合またはスフェロプラスト融合後、完全な重鎖ポリペプチド及び軽鎖ポリペプチドからなる完全な免疫グロブリンの発現と分泌を提供する発現コンストラクトを含むことになり、該安定した2倍体ピキア パストリス(Pichia pastoris)酵母細胞は、該2倍体ピキア パストリス(Pichia pastoris)酵母細胞を含む培養培地中に該イムノグロブリンを組み立てて長期間発現及び分泌させることが出来;
(ii) 該接合またはスフェロプラスト融合後、該2倍体ピキア パストリス(Pichia pastoris)酵母細胞を単離し;完全な免疫グロブリンが発現し、培養培地中に少なくとも500mg/Lの割合で分泌するような条件下で該2倍体ピキア パストリス(Pichia pastoris)酵母細胞を培養し;
(iii) 培養培地から該完全な免疫グロブリンを回収する;
ステップを含む方法。 - 前記接合またはスフェロプラスト融合が、
第一の酵母プロモーターに作動可能に結合された、該免疫グロブリンの完全な重鎖ポリペプチドまたは軽鎖ポリペプチドから選択される1つのサブユニットを発現するようにコードされた塩基配列を含む、第一の発現コンストラクトを含む第一の酵母1倍体細胞と;
第二の酵母プロモーターに作動可能に結合された、該免疫グロブリンの残りのサブユニットを発現するようにコードされた塩基配列を含む、第二の発現コンストラクトを含む第二の酵母1倍体細胞を;
接合または融合させることを目的とする;
請求項1に記載の方法。 - 免疫グロブリンがヒト、キメラ及びヒト化免疫グロブリンから選択される、請求項1に記載の方法。
- 前記発現コンストラクトが前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞のゲノムに挿入される、請求項1に記載の方法。
- 前記発現コンストラクトが染色体外プラスミドエレメントに含まれる、請求項1に記載の方法。
- 第一又は第二のプロモーターが構成型プロモーターである、請求項2に記載の方法。
- 第一又は第二のプロモーターが誘導型プロモーターである、請求項2に記載の方法。
- 前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞が最小培地で増殖する、請求項1に記載の方法。
- 前記最小培地が選択用薬剤を含まない、請求項8に記載の方法。
- 前記最小培地が前もって作られたアミノ酸および他の複雑な生体分子を欠く、請求項8に記載の方法。
- 前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞が少なくとも50g/Lまで増殖される請求項1に記載の方法。
- 前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞が少なくとも100g/Lまで増殖される請求項1に記載の方法。
- 前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞が少なくとも300g/Lまで増殖される請求項1に記載の方法。
- 前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞が少なくとも400g/Lまで増殖される請求項1に記載の方法。
- 前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞が少なくとも500g/Lまで増殖される請求項1に記載の方法。
- 前記生物学的に活性のある完全な免疫グロブリンの発現分泌レベルが培養中少なくとも1000mg/Lとなるよう、前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞が増殖する、請求項1に記載の方法。
- 前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞が少なくとも20倍化するまで培養され、該20倍化後に少なくとも500mg/Lのレベルの前記完全な免疫グロブリンの発現分泌が維持されている、請求項1に記載の方法。
- 前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞が少なくとも50倍化するまで培養され、該50倍化後に少なくとも500mg/Lのレベルの前記完全な免疫グロブリンの発現分泌が維持されている、請求項1に記載の方法。
- 前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞が少なくとも100倍化するまで培養され、該100倍化後に少なくとも500mg/Lのレベルの前記完全な免疫グロブリンの発現分泌が維持されている、請求項1に記載の方法。
- 前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞が少なくとも20倍化するまで培養され、該20倍化後、前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞の少なくとも99%が前記完全な免疫グロブリンを構成する前記重鎖及び軽鎖ポリペプチドの発現を提供する発現コンストラクトを含む、請求項1に記載の方法。
- 前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞が少なくとも50倍化するまで培養され、該50倍化後、前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞の少なくとも99%が前記完全な免疫グロブリンを構成する前記重鎖及び軽鎖ポリペプチドの発現を提供する発現コンストラクトを含む、請求項20に記載の方法。
- 前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞が少なくとも100倍化するまで培養され、該100倍化後、前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞の少なくとも99%が前記完全な免疫グロブリンを構成する前記重鎖及び軽鎖ポリペプチドの発現を提供する発現コンストラクトを含む、請求項21に記載の方法。
- 前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞が少なくとも20倍化するまで培養され、該20倍化後、前記完全な免疫グロブリンの発現が最初の発現レベルに較べて20%以下しか減少していないレベルで発現している、請求項1に記載の方法。
- 前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞が少なくとも50倍化するまで培養され、該50倍化後、前記完全な免疫グロブリンの発現が最初の発現レベルに較べて20%以下しか減少していないレベルで発現している、請求項1に記載の方法。
- 前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞が少なくとも100倍化するまで培養され、該100倍化後、前記完全な免疫グロブリンの発現が最初の発現レベルに較べて20%以下しか減少していないレベルで発現している、請求項1に記載の方法。
- 前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞が前記完全な免疫グロブリンを最初の発現レベルに較べて10%以下しか減少していないレベルで発現している、請求項23−25のいずれか一項に記載の方法。
- 前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞が前記完全な免疫グロブリンを最初の発現レベルに較べて5%以下しか減少していないレベルで発現している、請求項23−25のいずれか一項に記載の方法。
- 前記2倍体ピキア パストリス(Pichia pastoris)酵母細胞が22度以下の温度で培養される、請求項1に記載の方法。
- 増殖培地が少なくとも500mg/Lまたはそれ以上の発現レベルの生物学的に活性のある完全な免疫グロブリンを含む、請求項1−3のいずれか一項に記載の安定な2倍体ピキア パストリス(Pichia pastoris)の培養物を含む培養培地。
- 前記完全な免疫グロブリンが培養培地の中に発現し、該培養培地中、前記2倍体ピキア パストリス(Pichia pastoris)細胞濃度が少なくとも50g/Lまたはそれ以上である、請求項1−3のいずれか一項に記載の安定した2倍体ピキア パストリス(Pichia pastoris)培養物を含む培養培地。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51387603P | 2003-10-22 | 2003-10-22 | |
US60/513,876 | 2003-10-22 | ||
PCT/US2004/035302 WO2005040395A1 (en) | 2003-10-22 | 2004-10-22 | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012029170A Division JP2012095669A (ja) | 2003-10-22 | 2012-02-14 | 一倍体接合方法を用いた酵母におけるヘテロ多量体のポリペプチド類の合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007508847A JP2007508847A (ja) | 2007-04-12 |
JP4994038B2 true JP4994038B2 (ja) | 2012-08-08 |
Family
ID=34520146
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006536888A Expired - Lifetime JP4994038B2 (ja) | 2003-10-22 | 2004-10-22 | 一倍体接合方法を用いた酵母におけるヘテロ多量体のポリペプチド類の合成方法 |
JP2012029170A Pending JP2012095669A (ja) | 2003-10-22 | 2012-02-14 | 一倍体接合方法を用いた酵母におけるヘテロ多量体のポリペプチド類の合成方法 |
JP2015000021A Expired - Lifetime JP5982504B2 (ja) | 2003-10-22 | 2015-01-05 | 一倍体接合方法を用いた酵母におけるヘテロ多量体のポリペプチド類の合成方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012029170A Pending JP2012095669A (ja) | 2003-10-22 | 2012-02-14 | 一倍体接合方法を用いた酵母におけるヘテロ多量体のポリペプチド類の合成方法 |
JP2015000021A Expired - Lifetime JP5982504B2 (ja) | 2003-10-22 | 2015-01-05 | 一倍体接合方法を用いた酵母におけるヘテロ多量体のポリペプチド類の合成方法 |
Country Status (17)
Country | Link |
---|---|
US (7) | US8268582B2 (ja) |
EP (2) | EP2330201B1 (ja) |
JP (3) | JP4994038B2 (ja) |
CN (2) | CN101979650B (ja) |
AU (2) | AU2004283299B2 (ja) |
CA (1) | CA2541651C (ja) |
DK (2) | DK2330201T3 (ja) |
ES (2) | ES2630224T3 (ja) |
HK (1) | HK1093222A1 (ja) |
HU (1) | HUE033349T2 (ja) |
IL (2) | IL174783A (ja) |
NO (1) | NO20062134L (ja) |
NZ (1) | NZ547279A (ja) |
PL (1) | PL1678314T3 (ja) |
PT (1) | PT1678314E (ja) |
SI (1) | SI1678314T1 (ja) |
WO (1) | WO2005040395A1 (ja) |
Families Citing this family (159)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201402712QA (en) | 2005-08-31 | 2014-08-28 | Merck Sharp & Dohme | Engineered anti-il-23 antibodies |
CN101600793B (zh) * | 2006-05-19 | 2013-06-26 | 奥尔德生物制药公司 | 用于获得抗原特异性b细胞的克隆群体的培养方法 |
KR100778219B1 (ko) | 2006-08-28 | 2007-11-29 | 한국생명공학연구원 | 교배형 특이적 유전자에 의해 조절되는 반수체 제조용형질전환 효모 균주의 제조 |
US7795411B2 (en) * | 2006-10-05 | 2010-09-14 | Fred Hutchinson Cancer Research Center | Vectors for expressing in vivo biotinylated recombinant proteins |
US8232372B2 (en) | 2006-12-14 | 2012-07-31 | Schering Corp. | Engineered anti-TSLP antibody |
JP2010517577A (ja) * | 2007-02-09 | 2010-05-27 | メディミューン,エルエルシー | 酵母細胞原形質膜による抗体ライブラリー提示 |
PT2426144T (pt) | 2007-02-23 | 2019-02-06 | Merck Sharp & Dohme | Anticorpos anti-il-23p19 fabricados por engenharia genética |
WO2008103473A1 (en) | 2007-02-23 | 2008-08-28 | Schering Corporation | Engineered anti-il-23p19 antibodies |
MX2009009283A (es) | 2007-02-28 | 2009-11-18 | Schering Corp | Anticuerpos anti-interleuquina -23r de ingenieria. |
US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US7906117B2 (en) * | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
HUE032563T2 (en) * | 2007-05-21 | 2017-09-28 | Alderbio Holdings Llc | Antibodies to IL-6 and their use |
WO2008144757A1 (en) * | 2007-05-21 | 2008-11-27 | Alder Biopharmaceuticals, Inc. | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
US9056905B2 (en) | 2007-05-21 | 2015-06-16 | Alderbio Holdings Llc | Antibodies to TNF-α and use thereof |
US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
MX365985B (es) | 2008-11-25 | 2019-06-21 | Alderbio Holdings Llc | Antagonistas de il-6 para aumentar la albumina y/o disminuir la crp. |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
MX340953B (es) | 2009-09-03 | 2016-07-29 | Merck Sharp & Dohme Corp * | Anticuerpos anti receptor del factor de necrosis tumoral inducido por glucocorticoides. |
EP2494046B1 (en) | 2009-10-30 | 2018-09-12 | Novartis AG | Universal fibronectin type iii bottom-side binding domain libraries |
MX2012005180A (es) | 2009-11-04 | 2012-06-08 | Merck Sharp & Dohme | Anticuerpo anti-linfopoyetina estromal timica (anti-tslp) modificado por tecnicas de ingenieria genetica. |
MX2012005927A (es) | 2009-11-24 | 2012-11-23 | Alder Biopharmaceuticals Inc | Anticuerpos para il-6 uso de los mismos. |
US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
GB201003701D0 (en) * | 2010-03-05 | 2010-04-21 | Cilian Ag | System for the expression of a protein |
AU2011248083B2 (en) | 2010-05-04 | 2015-09-10 | Five Prime Therapeutics, Inc. | Antibodies that bind CSF1R |
AU2011332817A1 (en) | 2010-11-23 | 2013-06-13 | Alder Biopharmaceuticals, Inc. | Anti-IL-6 antibodies for the treatment of anemia |
US8911734B2 (en) | 2010-12-01 | 2014-12-16 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
AU2012205384B2 (en) | 2011-01-14 | 2015-09-10 | Five Prime Therapeutics, Inc. | IL-27 antagonists for treating inflammatory diseases |
TWI609888B (zh) | 2011-05-20 | 2018-01-01 | 艾爾德生物控股有限責任公司 | 抗降血鈣素基因相關胜肽(anti-cgrp)或抗降血鈣素基因相關胜肽受器(anti-cgrp-r)抗體或抗體片段治療或預防慢性及急性型腹瀉之用途 |
ES2899381T3 (es) | 2011-05-20 | 2022-03-11 | H Lundbeck As | Producción de alta pureza de proteínas de múltiples subunidades, tales como anticuerpos en microbios transformados, tal como Pichia pastoris |
EP4115905A1 (en) | 2011-05-20 | 2023-01-11 | H. Lundbeck A/S | Anti-cgrp compositions and use thereof |
EP2709663B1 (en) | 2011-05-20 | 2019-03-20 | AlderBio Holdings LLC | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
US10150968B2 (en) | 2011-08-19 | 2018-12-11 | Alderbio Holdings Llc | Multi-copy strategy for high-titer and high-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
TWI666318B (zh) * | 2011-08-19 | 2019-07-21 | 美商艾爾德生物控股有限責任公司 | 在經轉形的微生物如巴斯德畢赤氏酵母中的多-複製策略用於多-次級單元的蛋白質如抗體之高效價且高純度生產技術 |
JP2015517490A (ja) | 2012-05-11 | 2015-06-22 | ファイブ プライム セラピューティックス インコーポレイテッド | コロニー刺激因子1受容体(csf1r)を結合させる抗体を用いて状態を治療する方法 |
WO2014004436A2 (en) | 2012-06-27 | 2014-01-03 | Merck Sharp & Dohme Corp. | Crystalline anti-human il-23 antibodies |
WO2014036357A1 (en) | 2012-08-31 | 2014-03-06 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
CN103911371B (zh) * | 2013-01-05 | 2016-05-04 | 中国科学院微生物研究所 | 一种酿酒酵母整合型表达载体 |
US20150366890A1 (en) | 2013-02-25 | 2015-12-24 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
US10202630B2 (en) | 2013-03-15 | 2019-02-12 | Alderbio Holdings Llc | Temperature shift for high yield expression of polypeptides in yeast and other transformed cells |
EP2970865B1 (en) | 2013-03-15 | 2020-09-02 | Alder Biopharmaceuticals, Inc. | Antibody purification and purity monitoring |
DK2971037T3 (da) | 2013-03-15 | 2019-10-14 | Alder Biopharmaceuticals Inc | Temperaturændring til ekspression med højt udbytte af polypeptider i gær og andre transformerede celler |
EP3016684B1 (en) | 2013-07-03 | 2022-02-23 | H. Lundbeck A/S | Regulation of glucose metabolism using anti-cgrp antibodies |
US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
WO2015003114A1 (en) | 2013-07-05 | 2015-01-08 | University Of Washington Through Its Center For Commercialization | Soluble mic neutralizing monoclonal antibody for treating cancer |
KR102516152B1 (ko) | 2013-08-01 | 2023-03-31 | 파이브 프라임 테라퓨틱스, 인크. | 비푸코실화된 항-fgfr2iiib 항체 |
CN103468595B (zh) * | 2013-09-24 | 2016-01-13 | 浙江海正药业股份有限公司 | 表达重组人血白蛋白的酵母菌、其构建方法及应用和表达重组人血白蛋白的方法 |
CN103710278A (zh) * | 2013-12-25 | 2014-04-09 | 江南大学 | 一种低产尿素的工业黄酒酵母代谢工程菌及其构建方法 |
WO2015138127A1 (en) | 2014-03-11 | 2015-09-17 | E. I. Du Pont De Nemours And Company | Tailored dispersion and formation of integrated particle systems via ph responsive groups |
SG11201610672YA (en) | 2014-06-23 | 2017-01-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
TWI711463B (zh) | 2014-10-29 | 2020-12-01 | 美商戊瑞治療有限公司 | 用於癌症之組合療法 |
WO2016070001A1 (en) | 2014-10-31 | 2016-05-06 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind b7-h4 |
WO2016100838A2 (en) | 2014-12-19 | 2016-06-23 | Alder Biopharmaceuticals, Inc. | Humanized anti-acth antibodies and use thereof |
CN107257806B (zh) | 2014-12-22 | 2021-08-10 | 戊瑞治疗有限公司 | 用于治疗pvns的抗csf1r抗体 |
US20160200815A1 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
EP3245231B1 (en) | 2015-01-16 | 2020-08-12 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
TWI719970B (zh) | 2015-03-23 | 2021-03-01 | 美商永斯醫療股份有限公司 | 針對icos之抗體 |
CN107709365A (zh) | 2015-04-13 | 2018-02-16 | 戊瑞治疗有限公司 | 癌症组合疗法 |
WO2016179194A1 (en) | 2015-05-04 | 2016-11-10 | Jounce Therapeutics, Inc. | Lilra3 and method of using the same |
WO2017019777A1 (en) * | 2015-07-27 | 2017-02-02 | Washington University | Toolkit for the production of post-translationally modified proteins |
US10865394B2 (en) | 2015-07-27 | 2020-12-15 | Washington University | Toolkit for the production of post-translationally modified proteins |
US10968277B2 (en) | 2015-10-22 | 2021-04-06 | Jounce Therapeutics, Inc. | Gene signatures for determining ICOS expression |
TWI791422B (zh) | 2015-11-23 | 2023-02-11 | 美商戊瑞治療有限公司 | 用於癌症治療之單獨fgfr2抑制劑或與免疫刺激劑組合 |
JP7116685B2 (ja) | 2016-04-15 | 2022-08-10 | エイチ. ルンドベック アー/エス | ヒト化抗pacap抗体及びそれらの使用 |
EP3491024A2 (en) | 2016-07-29 | 2019-06-05 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies against anti-cd19 antibodies |
HRP20211703T1 (hr) | 2016-11-02 | 2022-02-04 | Jounce Therapeutics, Inc. | Protutijela protiv pd-1 i njihova upotreba |
WO2018133837A1 (en) | 2017-01-20 | 2018-07-26 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Anti-pd-1 antibodies and uses thereof |
US20200024351A1 (en) | 2017-04-03 | 2020-01-23 | Jounce Therapeutics, Inc. | Compositions and Methods for the Treatment of Cancer |
SG10202112636SA (en) | 2017-05-16 | 2021-12-30 | Five Prime Therapeutics Inc | Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment |
WO2019000223A1 (en) | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF |
SG11202003501XA (en) | 2017-11-01 | 2020-05-28 | Juno Therapeutics Inc | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
CA3082010A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for b-cell maturation antigen (bcma) |
CA3025536A1 (en) | 2017-12-01 | 2019-06-01 | Pfizer, Inc. | Anti-cxcr5 antibodies and compositions and uses thereof |
MA51184A (fr) | 2017-12-15 | 2020-10-21 | Juno Therapeutics Inc | Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés |
WO2019126514A2 (en) | 2017-12-22 | 2019-06-27 | Jounce Therapeutics, Inc. | Antibodies for lilrb2 |
MX2020010183A (es) | 2018-03-29 | 2022-11-28 | Pfizer | Variantes y composiciones del lfa3 y sus usos. |
EP3818085A4 (en) | 2018-06-01 | 2022-03-09 | Tayu Huaxia Biotech Medical Group Co., Ltd. | COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DISEASES OR DISORDERS |
SG11202100096XA (en) | 2018-07-09 | 2021-02-25 | Five Prime Therapeutics Inc | Antibodies binding to ilt4 |
US11447556B2 (en) | 2018-08-13 | 2022-09-20 | Inhibex, Inc. | OX40-binding polypeptides and uses thereof |
MX2021002690A (es) | 2018-09-07 | 2021-05-12 | Pfizer | Anticuerpos anti-avb8 y composiciones y usos de los mismos. |
US20210275590A1 (en) | 2018-09-10 | 2021-09-09 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against cd33 and constructs thereof |
EP3864045A2 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
WO2020076992A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | 5t4 single domain antibodies and therapeutic compositions thereof |
CN113166262A (zh) | 2018-10-11 | 2021-07-23 | 英伊布里克斯公司 | Pd-1单结构域抗体及其治疗组合物 |
WO2020076970A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | B7h3 single domain antibodies and therapeutic compositions thereof |
US20210393690A1 (en) | 2018-11-01 | 2021-12-23 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
EP3873937A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
BR112021012294A2 (pt) | 2019-01-07 | 2021-09-08 | Inhibrx, Inc. | Polipeptídeos compreendendo polipeptídeos de il-2 modificada e usos dos mesmos |
SG11202106766SA (en) | 2019-01-08 | 2021-07-29 | H Lundbeck As | Acute treatment and rapid treatment of headache using anti-cgrp antibodies |
WO2020160050A1 (en) | 2019-01-29 | 2020-08-06 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
EP3938396A1 (en) | 2019-03-11 | 2022-01-19 | Jounce Therapeutics, Inc. | Anti-icos antibodies for the treatment of cancer |
SG11202111731WA (en) | 2019-05-04 | 2021-11-29 | Inhibrx Inc | Clec12a-binding polypeptides and uses thereof |
US11434297B2 (en) | 2019-05-04 | 2022-09-06 | Inhibrx, Inc. | CD123-binding polypeptides and uses thereof |
BR112021021048A2 (pt) | 2019-05-04 | 2021-12-14 | Inhibrx Inc | Polipeptídeos que se ligam a cd33 e seus usos |
CN114787188A (zh) | 2019-11-05 | 2022-07-22 | 震动疗法股份有限公司 | 用抗pd-1抗体治疗癌症的方法 |
MX2022006709A (es) | 2019-12-06 | 2022-09-12 | Juno Therapeutics Inc | Anticuerpos antiidiotípicos para dominios de unión dirigidos a bcma y métodos y composiciones relacionadas. |
US20230192869A1 (en) | 2019-12-06 | 2023-06-22 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods |
JP2023517794A (ja) | 2020-01-06 | 2023-04-27 | ハイファイバイオ(ホンコン)リミテッド | 抗tnfr2抗体及びその使用 |
US20230054718A1 (en) | 2020-01-07 | 2023-02-23 | Hifibio (Hk) Limited | Anti-galectin-9 antibody and uses thereof |
MX2022009306A (es) | 2020-01-29 | 2022-09-26 | Inhibrx Inc | Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos. |
PE20231067A1 (es) | 2020-02-14 | 2023-07-17 | Jounce Therapeutics Inc | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos |
CN115151573A (zh) | 2020-02-28 | 2022-10-04 | 上海复宏汉霖生物技术股份有限公司 | 抗cd137构建体、多特异性抗体及其用途 |
BR112022016491A2 (pt) | 2020-02-28 | 2022-10-11 | Shanghai Henlius Biotech Inc | Construto anti-cd137 e usos do mesmo |
CN115916223A (zh) | 2020-04-10 | 2023-04-04 | 朱诺治疗学股份有限公司 | 与用靶向b细胞成熟抗原的嵌合抗原受体工程化的细胞疗法相关的方法和用途 |
WO2021216417A1 (en) | 2020-04-20 | 2021-10-28 | Jounce Therapeutics, Inc. | Compositions and methods for vaccination and the treatment of infectious diseases |
JP2023524995A (ja) | 2020-05-04 | 2023-06-14 | インヒブルクス インコーポレイテッド | イヌpd-1結合性ポリペプチド及びその使用 |
CN116529260A (zh) | 2020-06-02 | 2023-08-01 | 当康生物技术有限责任公司 | 抗cd93构建体及其用途 |
KR20230037532A (ko) | 2020-06-02 | 2023-03-16 | 다이내믹큐어 바이오테크놀로지 엘엘씨 | 항-cd93 구축물 및 그의 용도 |
KR20230035076A (ko) | 2020-07-02 | 2023-03-10 | 인히브릭스, 인크. | 변형된 il-2 폴리펩티드를 포함하는 폴리펩티드 및 이의 용도 |
TW202216776A (zh) | 2020-07-07 | 2022-05-01 | 美商康愈有限責任公司 | Mic抗體及結合劑以及其使用方法 |
JP2023536461A (ja) | 2020-07-29 | 2023-08-25 | ダイナミキュア バイオテクノロジー エルエルシー | 抗cd93構築物およびその使用 |
KR20230095918A (ko) | 2020-08-05 | 2023-06-29 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ror1-표적 결합 도메인에 대한 항이디오타입 항체 및 관련 조성물 및 방법 |
WO2022033419A2 (en) | 2020-08-10 | 2022-02-17 | Shanghai Xbh Biotechnology Co., Ltd. | Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8 |
CN111944708B (zh) * | 2020-08-27 | 2022-04-01 | 宜宾五粮液股份有限公司 | 高产乙酸异戊酯的酵母及其应用 |
US20240011016A1 (en) * | 2020-11-23 | 2024-01-11 | Merck Sharp & Dohme Llc | Full-length human immunoglobulin g antibody libraries for surface display and secretion in saccharomyces cerevisiae |
US11720540B2 (en) | 2020-12-30 | 2023-08-08 | Itron, Inc. | Secure blockchain data recovery |
AU2022218137A1 (en) | 2021-02-03 | 2023-08-24 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
EP4294842A1 (en) | 2021-02-19 | 2023-12-27 | Inhibrx, Inc. | Formulations of dr5 binding polypeptides |
JP2024509191A (ja) | 2021-03-05 | 2024-02-29 | ダイナミキュア バイオテクノロジー エルエルシー | 抗vista構築物およびその使用 |
TW202300648A (zh) | 2021-03-25 | 2023-01-01 | 美商當康生物科技有限公司 | 抗-igfbp7構築體及其用途 |
WO2022217022A1 (en) | 2021-04-10 | 2022-10-13 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
AU2022262644A1 (en) | 2021-04-23 | 2023-11-09 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
WO2022241057A1 (en) | 2021-05-12 | 2022-11-17 | Applied Biomedical Science Institute | Binding polypeptides against sars cov-2 and uses thereof |
WO2022266660A1 (en) | 2021-06-17 | 2022-12-22 | Amberstone Biosciences, Inc. | Anti-cd3 constructs and uses thereof |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
EP4359794A1 (en) | 2021-07-13 | 2024-05-01 | Keystone Bio, Inc. | Diagnostics for porphyromonas gingivalis |
EP4373854A1 (en) | 2021-07-20 | 2024-05-29 | Inhibrx, Inc. | Cd8-binding polypeptides and uses thereof |
WO2023004305A1 (en) | 2021-07-20 | 2023-01-26 | Inhibrx, Inc. | Cd8-targeted modified il-2 polypeptides and uses thereof |
WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
JP2024540536A (ja) | 2021-11-19 | 2024-10-31 | アーディアジェン コーポレーション | Gpc3結合剤、そのコンジュゲートおよびその使用方法 |
CA3242658A1 (en) | 2022-01-05 | 2023-07-13 | Bryan R. Becklund | Gamma delta t-cell-binding polypeptides and uses thereof |
WO2023133393A1 (en) | 2022-01-05 | 2023-07-13 | Inhibrx, Inc. | Gamma delta t-cell-targeted modified il-2 polypeptides and uses thereof |
AU2023221861A1 (en) | 2022-02-18 | 2024-09-05 | Rakuten Medical, Inc. | Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use |
WO2023196943A1 (en) | 2022-04-08 | 2023-10-12 | Inhibrx, Inc. | Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy |
WO2023215810A1 (en) | 2022-05-05 | 2023-11-09 | Inhibrx, Inc. | Albumin-binding polypeptides and uses thereof |
WO2023230432A1 (en) | 2022-05-23 | 2023-11-30 | Inhibrx, Inc. | Dr5 agonist and iap antagonist combination therapy |
WO2023230488A1 (en) | 2022-05-23 | 2023-11-30 | Cereius, Inc. | Her2-binding agents and uses thereof |
WO2023235699A1 (en) | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
TW202409086A (zh) | 2022-06-11 | 2024-03-01 | 美商英伊布里克斯公司 | FcRn-結合多肽及其用途 |
WO2024006975A1 (en) | 2022-07-01 | 2024-01-04 | Bristol-Myers Squibb Company | Methods for antibody humanization |
WO2024015993A1 (en) | 2022-07-15 | 2024-01-18 | Fibrogen, Inc. | Modified anti-galectin-9 antibody and uses thereof |
US20240228664A9 (en) | 2022-07-22 | 2024-07-11 | Bristol-Myers Squibb Company | Antibodies Binding to Human PAD4 and Uses Thereof |
WO2024030956A2 (en) | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Cd39-specific binding agents and methods of using the same |
WO2024031091A2 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
WO2024040216A2 (en) | 2022-08-19 | 2024-02-22 | Fibrogen, Inc. | Anti-ccr8 antibodies and uses thereof |
WO2024044779A2 (en) | 2022-08-26 | 2024-02-29 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3) |
WO2024054929A1 (en) | 2022-09-07 | 2024-03-14 | Dynamicure Biotechnology Llc | Anti-vista constructs and uses thereof |
WO2024102948A1 (en) | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
US20240226298A1 (en) | 2022-12-13 | 2024-07-11 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof |
WO2024216064A1 (en) | 2023-04-14 | 2024-10-17 | Twist Bioscience Corporation | Compositions and methods related to dkk1 binders |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4775622A (en) * | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
WO1987002671A1 (en) * | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US6306625B1 (en) | 1988-12-30 | 2001-10-23 | Smithkline Beecham Biologicals, Sa | Method for obtaining expression of mixed polypeptide particles in yeast |
US5545727A (en) * | 1989-05-10 | 1996-08-13 | Somatogen, Inc. | DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin |
AU6275690A (en) | 1989-08-09 | 1991-03-11 | Delta Biotechnology Limited | Polypeptide production in fungi |
GB8927480D0 (en) | 1989-12-05 | 1990-02-07 | Delta Biotechnology Ltd | Mutant fungal strain detection and new promoter |
US5202422A (en) | 1989-10-27 | 1993-04-13 | The Scripps Research Institute | Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
JPH06506117A (ja) * | 1991-04-01 | 1994-07-14 | メルク エンド カンパニー インコーポレーテッド | ピキア(Pichia)蛋白質分解活性に影響する遺伝子およびその使用 |
US5330901A (en) * | 1991-04-26 | 1994-07-19 | Research Corporation Technologies, Inc. | Expression of human serum albumin in Pichia pastoris |
US5440018A (en) * | 1992-05-20 | 1995-08-08 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
DK0682710T3 (da) | 1993-02-10 | 2004-03-01 | Unilever Nv | Isolationsmetode, ved hvilken der anvendes immobiliserede proteiner med specifikke kapaciteter |
AU6445894A (en) | 1993-03-19 | 1994-10-11 | Duke University | Method of treatment of tumors with an antibody binding to tenascin |
JP3053873B2 (ja) | 1994-08-12 | 2000-06-19 | イムノメディクス,インコーポレイテッド | B細胞リンパ腫細胞および白血病細胞に特異的な免疫結合体およびヒト化抗体 |
GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
US6232111B1 (en) * | 1996-04-10 | 2001-05-15 | Merck & Co., Inc. | Method for improving culture medium for recombinant yeast |
US20010036647A1 (en) * | 1998-10-22 | 2001-11-01 | Prabhakara V. Choudary | Functionally assembled antigen-specific intact recombinant antibody and a method for production thereof |
US6258559B1 (en) * | 1999-03-22 | 2001-07-10 | Zymogenetics, Inc. | Method for producing proteins in transformed Pichia |
WO2003016525A1 (fr) | 2001-08-16 | 2003-02-27 | Kansai Chemical Engineering Co., Ltd. | Procede de production d'alcool a partir d'amidon |
AU2002332598A1 (en) * | 2001-08-22 | 2003-03-10 | Shengfeng Li | Compositions and methods for generating antigen-binding units |
DK2093286T3 (da) * | 2001-10-01 | 2013-05-13 | Dyax Corp | Flerkædede, eukaryote displayvektorer og anvendelser deraf |
US20060121565A1 (en) * | 2002-09-20 | 2006-06-08 | Cymip A/S | Methods for increasing the production of a recombinant polypeptide from a host cell |
-
2004
- 2004-10-22 US US10/577,074 patent/US8268582B2/en active Active
- 2004-10-22 EP EP10183188.1A patent/EP2330201B1/en not_active Expired - Lifetime
- 2004-10-22 ES ES10183188.1T patent/ES2630224T3/es not_active Expired - Lifetime
- 2004-10-22 SI SI200431956T patent/SI1678314T1/sl unknown
- 2004-10-22 CN CN201010512807.5A patent/CN101979650B/zh not_active Expired - Lifetime
- 2004-10-22 PL PL04796313T patent/PL1678314T3/pl unknown
- 2004-10-22 DK DK10183188.1T patent/DK2330201T3/en active
- 2004-10-22 JP JP2006536888A patent/JP4994038B2/ja not_active Expired - Lifetime
- 2004-10-22 AU AU2004283299A patent/AU2004283299B2/en not_active Ceased
- 2004-10-22 ES ES04796313T patent/ES2393555T3/es not_active Expired - Lifetime
- 2004-10-22 PT PT04796313T patent/PT1678314E/pt unknown
- 2004-10-22 DK DK04796313.7T patent/DK1678314T3/da active
- 2004-10-22 EP EP04796313A patent/EP1678314B1/en not_active Expired - Lifetime
- 2004-10-22 HU HUE10183188A patent/HUE033349T2/en unknown
- 2004-10-22 CN CN2004800312173A patent/CN1871359B/zh not_active Expired - Lifetime
- 2004-10-22 CA CA2541651A patent/CA2541651C/en not_active Expired - Lifetime
- 2004-10-22 WO PCT/US2004/035302 patent/WO2005040395A1/en active Application Filing
- 2004-10-22 NZ NZ547279A patent/NZ547279A/en not_active IP Right Cessation
-
2006
- 2006-04-04 IL IL174783A patent/IL174783A/en active IP Right Grant
- 2006-05-08 US US11/429,053 patent/US7927863B2/en active Active
- 2006-05-12 NO NO20062134A patent/NO20062134L/no not_active Application Discontinuation
-
2007
- 2007-01-09 HK HK07100300.8A patent/HK1093222A1/xx not_active IP Right Cessation
-
2009
- 2009-09-11 AU AU2009213095A patent/AU2009213095B2/en not_active Ceased
-
2011
- 2011-02-24 IL IL211402A patent/IL211402A/en active IP Right Grant
- 2011-03-24 US US13/070,583 patent/US9873746B2/en active Active
-
2012
- 2012-02-14 JP JP2012029170A patent/JP2012095669A/ja active Pending
- 2012-08-30 US US13/598,885 patent/US8709756B2/en not_active Expired - Lifetime
-
2014
- 2014-01-28 US US14/165,896 patent/US10155819B2/en not_active Expired - Lifetime
-
2015
- 2015-01-05 JP JP2015000021A patent/JP5982504B2/ja not_active Expired - Lifetime
- 2015-09-14 US US14/853,292 patent/US10259883B2/en not_active Expired - Lifetime
-
2019
- 2019-03-11 US US16/297,966 patent/US11447560B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5982504B2 (ja) | 一倍体接合方法を用いた酵母におけるヘテロ多量体のポリペプチド類の合成方法 | |
US9765321B2 (en) | P. pastoris pastoris promoters, and the use thereof to direct expression of proteins in yeast, preferably using a haploid mating strategy | |
JP5859202B2 (ja) | 新規のウサギ抗体ヒト化方法及びヒト化ウサギ抗体 | |
CA2177988A1 (en) | Expression vector for preparing an anti-body-variable-region library | |
TW201313899A (zh) | 在經轉形的微生物如巴斯德畢赤氏酵母中的多-複製策略用於多-次級單元的蛋白質如抗體之高效價且高純度生產技術 | |
US11214610B2 (en) | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris | |
MXPA06004334A (es) | Metodos de sintetizacion de polipetidos heteromultimericos en levadura utilizando una estrategia de apareamiento haploide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071017 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100803 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101028 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110125 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110125 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111014 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120214 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120316 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120413 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120508 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150518 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4994038 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |